VantAI Announces Formation of Scientific Advisory Board NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- VantAI, a leading company focused on the application of artificial intelligence to drug discovery, today announced its newly formed Scientific Advisory...

Geometric Deep Learning Pioneer Michael Bronstein joins VantAI as Chief Scientist in Residence to Help Drive Artificial Intelligence Breakthroughs in Drug Discovery NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- VantAI, a leader in ML technologies for drug discovery, is excited to announce the appointment of Dr. Michael Bronstein as Chief Scientist in Residence....

VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders VantAI will pair its induced proximity platform with BI’s deep early discovery experience to identify targeted protein degraders with enhanced properties for traditionally “undruggable” targets NEW...

VantAI Announces Multi-Year Protein Degrader Discovery Collaboration with Janssen NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- VantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV,...